GUFICBIOGufic Biosciences Ltd.

    Gufic Biosciences Q2 FY27 Results: Consolidated Net Profit ₹23.47 Crore on Total Income of ₹289 Crore

    • Earnings
    • Pharmaceuticals
    A dark wooden apothecary cabinet with small drawers and shelves holding white and blue glass medicine bottles, in a museum display.
    先従隗始, via Wikimedia Commons (CC0). Illustrative image.

    Gufic Biosciences (NSE: GUFICBIO) reported consolidated total income of ₹289.40 crore and net profit of ₹23.47 crore for the quarter ended 30 Sep 2026, it said in a filing on 14 Nov 2026. Standalone total income was ₹289.53 crore and standalone net profit ₹23.49 crore.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹289.40 crore, up 21.0% YoY and 10.8% QoQ
    • Net profit and EPS: ₹23.47 crore, up 39.5% YoY; basic EPS ₹2.34
    • Finance costs: ₹10.44 crore, up 8.9% YoY and 12.0% QoQ

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹289.53 crore, up 24.5% YoY and 10.8% QoQ
    • Net profit and EPS: ₹23.49 crore, up 57.3% YoY; basic EPS ₹2.34
    • Finance costs: ₹10.44 crore, up 8.9% YoY and 12.0% QoQ

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    289.40239.17+21.0%261.28+10.8%
    23.4716.82+39.5%22.31+5.2%
    EPS, basic (₹)2.341.68+39.3%2.22+5.4%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Profit grew faster than income on a year-earlier basis. Consolidated net profit rose 39.5% against total income growth of 21.0%, and profit before tax rose 39.1%. Tax expense rose 38.0%, close to the pace of profit, so the tax line did not change the gap.

    Other income fell 46.8% to ₹1.12 crore, which is 0.4% of total income and 3.6% of profit before tax. Revenue from operations, at ₹288.27 crore, carries almost all of the growth. Finance costs of ₹10.44 crore are 3.6% of total income, up 8.9% on the year-earlier quarter.

    Depreciation was flat at ₹7.73 crore, so the step-up in profit sits above the depreciation line. The notes state no exceptional items for the quarter.

    The consolidated statement includes Gufic UK Limited, Veira Life FZE, Gufic Ireland Limited and Gufic Prime Private Limited. Consolidated net profit of ₹23.47 crore is ₹0.02 crore below standalone, a near-identical result.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    289.53232.51+24.5%261.28+10.8%
    23.4914.94+57.3%22.46+4.6%
    EPS, basic (₹)2.341.49+57.0%2.24+4.5%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone net profit rose 57.3% YoY to ₹23.49 crore, faster than total income (up 24.5%) and profit before tax (up 53.4%). Standalone tax expense of ₹8.00 crore is 25.4% of profit before tax of ₹31.49 crore.

    Standalone revenue from operations rose 25.2% to ₹288.40 crore, while other income fell 46.2% to ₹1.12 crore. Other income is 3.6% of profit before tax, so the quarter's profit rests almost entirely on operations.

    Against the previous quarter, standalone net profit rose 4.6% and total income rose 10.8%. The company is a single pharmaceuticals segment, so there is no segment split to compare.

    For context, Blacklitt's data shows a market value of ₹4,744 crore and a Q1 FY27 consolidated net profit of ₹22.31 crore, up 70.7% YoY.

    Inference

    The filing reports that the Board approved the results on 14 Nov 2026 and that the Statutory Auditors carried out a limited review, with no audit opinion expressed. The filing does not state whether any dividend is declared for the period, and it does not give the reason for the rise in other expenses or the increase in inventories and trade receivables, nor the reason for the rise in current borrowings.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts